Digital Mammography More Accurate in Younger Women

News
Article
Oncology NEWS InternationalOncology NEWS International Vol 14 No 10
Volume 14
Issue 10

ARLINGTON, Virginia-Data from more than 40,000 women who underwent both digital and film mammography at 33 sites in the US and Canada show that, while the techniques have similar overall diagnostic accuracy in breast cancer screening, digital mammography is more accurate in women under the age of 50 years, women with radiographically dense breasts, and pre- or perimenopausal women.

ARLINGTON, Virginia-Data from more than 40,000 women who underwent both digital and film mammography at 33 sites in the US and Canada show that, while the techniques have similar overall diagnostic accuracy in breast cancer screening, digital mammography is more accurate in women under the age of 50 years, women with radiographically dense breasts, and pre- or perimenopausal women.

DMIST Study

Lead investigator Etta D. Pisano, MD, professor of radiology and biomedical engineering and chief of breast imaging at the University of North Carolina School of Medicine, Chapel Hill, presented the results of the Digital Mammographic Imaging Screening Trial (DMIST) at the fall meeting of the American College of Radiology Imaging Network (ACRIN).

The $26.5 million trial was funded by the National Cancer Institute and conducted by ACRIN. Results were published in the New England Journal ofMedicine (online ahead of print on September 16, 2005). Beginning in October 2001, DMIST enrolled 49,528 women who had no signs of breast cancer. Women were given both digital and film mammograms, which were interpreted independently by two different radiologists.

Breast cancer status was ascertained based on a breast biopsy performed within 15 months of study entry or through follow-up mammography at least 10 months after study entry. All relevant information in accordance with study protocol was available for 42,760 women (86.3%).

Patient Characteristics

Mean age of the 42,760 women with verified breast cancer status was 54.9 years. Nearly 85% were Caucasian. Nearly two-thirds were postmenopausal. Among these women, 14,335 were under the age of 50 years, 19,897 had heterogeneously or extremely dense breasts, and 15,803 were premenopausal or perimenopausal. Receiver-operating-characteristic (ROC) analysis was used to evaluate the results.

Diagnostic accuracy of digital and film mammography was similar, with the difference between the methods in the area under the ROC curve at 0.03 (P = .18). Key patient subsets, however, realized a diagnostic performance benefit with digital mammography: Compared with film mammography, the accuracy of digital mammography was significantly higher among women under the age of 50 years (difference in AUC 0.15, P = .002); women with heterogeneously or extremely dense breasts on mammography (AUC difference 0.11, P = .003); and premenopausal or perimenopausal women (AUC difference 0.15, P = .002).

Emphasizing that breast cancers detected by digital mammography in these three patient subsets "included many invasive and high-grade in situ cases ........precisely the lesions that must be detected early to save lives through screening," the DMIST investigators concluded that "the significant improvement in accuracy of specific subgroups of women justifies use of digital mammography in these groups."

Recent Videos
Findings from David Rimm, MD, PhD, suggest that there may be an inverse relationship between HER2 and TROP2 expression among patients with breast cancer.
Tissue samples collected from patients with breast cancer during treatment may help explore therapy selection and predict toxicities.
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
First-degree relatives of patients who passed away from pancreatic cancer should be genetically tested to identify their risk for the disease.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
Related Content